Jul. 15 at 2:28 PM
$BCTX Allogeneic cell therapies are notoriously hard to scale.
Only a handful of CDMOs globally have regulatory‑approved, cGMP‑ready suites for this category.
FUJIFILM’s Thousand Oaks facility is purpose‑built for advanced therapies, with cGMP suites, QC labs, and global regulatory compliance baked in .
BriaCell didn’t just get a manufacturer — they got the manufacturer you’d want.
FUJIFILM is providing capacity for the entire remainder of Phase 3
The release states the arrangement “provides manufacturing capacity for the remainder of BriaCell’s pivotal Phase 3 study” .
That signals:
FUJIFILM reviewed Bria‑IMT’s process and deemed it manufacturable.
FUJIFILM believes the program is stable enough to commit capacity.
BriaCell now has locked‑in supply for the pivotal trial — eliminating one of the biggest risks in cell therapy development.
This is a major de‑risking event.
CDMOs do not offer commercial‑scale commitments lightly.
This implies:
FUJIFILM sees a viable path to approval.
